Mastering Mutation-Driven mCRC: From Testing to Targeted Therapy

Mutational Testing in mCRC: Methods and Data Driving Treatment Selection

MinuteCE®
ReachMD Healthcare Image
Media formats available:
Details
Episodes
Presenters
  • Overview

    In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, the management of treatment-related adverse events. 

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:

    Fortunato Ciardiello, MD, PhD
    Professor of Medical Oncology
    Università degli Studi della Campania Luigi Vanvitelli
    Naples, Italy

    Dr. Ciardiello has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:

    Research: Merck KgaA Pfizer, Roche, Servier.
    Consulting Fees: Merck KgaA, Pfizer, Roche and Servier.

    Jenny Seligmann, MBChB, PhD
    Professor of Gastrointestinal and Translational Oncology
    University of Leeds
    Leeds, UK

    Dr. Seligmann has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:

    Consulting Fees: GSK, Johnson & Johnson, Merck, Pierre Fabre Ltd, Serono, Servier
    Research: GSK, Merck, Pierre Fabre Medicament, Serono

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has no relevant relationships to disclose.
    • Jocelyn Timko has no relevant relationships to disclose.
    • Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Apply methods and data supporting molecular testing in colorectal cancer, including simultaneous BRAF and RAS testing, preferred approaches, and appropriate timing to guide optimal treatment selection in metastatic colorectal cancer (mCRC) 
    • Evaluate current and emerging data in targeted treatment combinations for mCRC, including BRAF-mutant mCRC 
    • Apply the most recent efficacy and safety evidence in targeted treatment combinations to optimize the management of mCRC, including BRAF-mutant mCRC 
    • Compare emerging treatment advances in mCRC, including the rationale behind novel targets and combination strategies 
  • Target Audience

    This activity has been designed to meet the educational needs of medical oncologists and pathologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with metastatic colorectal cancer (mCRC).

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0contact hour/0.1 CEUs of pharmacy contact hours. 

    The Universal Activity Number for this program is JA0006235-0000-25-039-H01-P . This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit(s). Approval is valid until 11/21/2026. PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    AGILEAcademy for Global Interprofessional Learning and Education – designs, develops and delivers education across a broad spectrum of diseases and clinical conditions. Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes. 

  • Commercial Support

    This activity is supported by an independent educational grant from Merck KGaA, Darmstadt, Germany 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and AGILE. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of AGILE you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site. 

    Reproduction Prohibited. Reproduction of this material is not permitted without written permission from the copyright owner. 

    Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement.”  

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date: Ongoing Program - Expiration date will be posted when all episodes are published.

NEW FEATURES:

Register

We're glad to see you're enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free